A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

The main inclusion criteria include but are not limited to the following:

• Has a histologically confirmed diagnosis of squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of cervix

• Has persistent, recurrent, or newly diagnosed metastatic (International Federation of Gynecology and Obstetrics [FIGO]-2028 Stage IVB) cervical cancer that is not amenable to curative treatment (surgery and/or radiation)

• If infected with human immunodeficiency virus (HIV), has well controlled HIV on antiretroviral therapy

• If positive for hepatitis B surface antigen, has received hepatitis B virus (HBV) antiviral therapy and has undetectable HBV viral load

• If has a history of hepatitis C virus (HCV) infection, has undetectable HCV viral load

• Has an Eastern Cooperative Oncology Group performance status of 0 or 1

• Has tumor programmed cell death ligand 1 expression of combined positive score ≥1

The main exclusion criteria include but are not limited to the following:

• Has HIV infection with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease

• Has a history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing

• Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea)

• Has uncontrolled, significant cardiovascular disease or cerebrovascular disease

• Has received prior systemic anticancer therapy other than what is specified in this protocol

• Is currently receiving a strong inducer/inhibitor of cytochrome P450 3A4 that cannot be discontinued for the duration of treatment with sac-TMT

• Has a diagnosis of immunodeficiency

• Has a known additional malignancy that is progressing or has required active treatment within the past 3 years

• Has known active central nervous system metastases and/or carcinomatous meningitis

• Has active autoimmune disease that has required systemic treatment in the past 2 years; replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed

• Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, has current pneumonitis/ILD, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments

• Has a history of stem cell/solid organ transplant

• Has not adequately recovered from major surgery or has ongoing surgical complications